Newronika
Founded 2016 · 26 employees on LinkedIn · 8 known investors
Newronika is a spin-off of Italian research institutions Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan that develops adaptive deep brain stimulation (αDBS) technology which responds to brain activity in real time. Its neuromodulation systems target Parkinson's disease and are being studied for a broader range of brain disorders, serving clinicians and patients.
Founders & leadership
Newronika was founded in 2016 by Lorenzo Rossi.
LR
Lorenzo RossiinFounder · Chief Executive Officer
Investors · 8
Also in the syndicate · 5
F3FFondazione ENEA Tech e BiomedicalleadIndaco Venture Partners SGRInnogest SGRTNBT Capital
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BFeb 2025
Fondazione ENEA Tech e Biomedical (lead), F3F, Indaco Venture Partners SGR, Innogest SGR, TNBT Capital, Wille Finance
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Newronika do?
- Newronika is a spin-off of Italian research institutions Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan that develops adaptive deep brain stimulation (αDBS) technology which responds to brain activity in real time. Its neuromodulation systems target Parkinson's disease and are being studied for a broader range of brain disorders, serving clinicians and patients.
- Who founded Newronika?
- Newronika was founded by Lorenzo Rossi in 2016.
- Who are Newronika's investors?
- Newronika's investors include Indaco Venture Partners, Innogest Capital, Wille Finance.